Prothena Corporation plc (PRTA) Stock Grade

About Prothena Corporation plc's fundamentals

Prothena Corporation is a small-cap biotechnology company with a market capitalization of $456.5 million that reported a significant net loss in its latest annual statement, reflected in an exceptionally negative net margin of -2520.6%. The company experienced a steep revenue decline of 92.8% year-over-year, indicating a substantial contraction in its business operations. As a pre-profitability biotech firm, Prothena does not pay a dividend and lacks meaningful P/E and ROE metrics. Investors should note that the company's financial metrics reflect the challenges typical of early-stage biotechnology companies, where profitability remains uncertain.